PhaseBio Pharmaceuticals Inc (PHAS) Stock
PHAS is no longer traded. PhaseBio Pharmaceuticals was delisted from the Nasdaq in January 2023.
Prices on this page are historical; the last trade was January 4, 2023 at $0.04.
PhaseBio Pharmaceuticals stock price history
PHAS final trading statistics
- Final close
- $0.04
- Final trading day
- Jan 4, 2023
- Market cap at delisting
- $1.99M
- Shares outstanding
- 49.86M
- Final 52-week range
- $0.01 – $2.60
- Avg. volume (final 3 mo.)
- 1,914,679
- All-time high (split-adj.)
- $14.66 · Apr 2019
- All-time low (split-adj.)
- $0.02 · Dec 2022
- Return since IPO
- -99.2%
- Beta
- 2.87
- Book value / share
- -$2.35
- Price / book
- -0.02
PhaseBio Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $10.8K | -$131.1K | -$3.03 |
| FY2020 | $320.0K | -$98.6M | -$3.39 |
| FY2019 | $2.36M | -$39.2M | -$1.42 |
| FY2018 | $668.0K | -$23.8M | -$12.05 |
| FY2017 | $0.00 | -$10.2M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About PhaseBio Pharmaceuticals Inc
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
PhaseBio Pharmaceuticals stock FAQ
What happened to PhaseBio Pharmaceuticals stock?
PhaseBio Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $0.04 on January 4, 2023.
Is PHAS stock still trading?
No. PHAS was delisted from the Nasdaq in January 2023 and no longer trades on a U.S. exchange.
What was the last price of PHAS stock?
PHAS closed at $0.04 on its final trading day, January 4, 2023, for a market value of about $1.99M.
What were PhaseBio Pharmaceuticals's revenue and earnings in its last full fiscal year?
PhaseBio Pharmaceuticals reported revenue of $10.8K and net income of -$131.1K in fiscal 2021, its last full year as a public company.
When did PhaseBio Pharmaceuticals go public?
PhaseBio Pharmaceuticals Inc stock began trading on October 18, 2018.